Navigation Links
Questcor to Report Second Quarter Financial Results on July 30, 2013
Date:7/12/2013

ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July  30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments..

The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website, http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The telephone dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 16591264.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
2. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
3. Questcor Adds Angus C. Russell to Board of Directors
4. Questcor Reports First Quarter Financial Results
5. Questcor to Report First Quarter Results on April 30, 2013
6. Questcor Reports Fourth Quarter and Full Year 2012 Results
7. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
8. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
10. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
11. Questcor to Conduct Conference Call to Discuss Reimbursement Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... Calif. (PRWEB) , ... December ... ... group Attorneys for the Rights of the Child (ARC) ( http://www.arclaw.org ) ... circumcision (VMMC) program in Africa, though only on boys mostly 15 years ...
(Date:12/9/2019)... Conn. and WALNUT CREEK, Calif. (PRWEB) , ... ... ... the nation’s leading technology-based solutions to optimize healthcare provider savings across purchased services ... Sharp is the leading healthcare provider in San Diego County with four acute ...
(Date:12/9/2019)... (PRWEB) , ... December 09, 2019 , ... ... cysts most people contend with are not ‘sebaceous,’” notes Dr. Robert Levine, a ... usually epidermoid – also called ‘epidermal’ – cysts, which have their own distinct ...
Breaking Medicine Technology:
(Date:12/14/2019)... ... December 14, 2019 , ... For two years, the only ... modular buildings. Driving into the parking lot would make you think of the temporary ... is simple. Hurricane Irma devastated the old building and the hospital carried on, first ...
(Date:12/9/2019)... , ... December 09, 2019 ... ... in innovative solutions that help food and manufacturing companies engage with their ... program. This turnkey solution helps manufacturers build a cohesive culture that is ...
(Date:12/8/2019)... ... December 08, 2019 , ... Intelligent.com, a trusted resource ... Logistics Degree Programs for 2020. The comprehensive research guide is based on an ... evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. , ...
(Date:12/6/2019)... ... December 06, 2019 , ... In ... students in Salt Lake Community College’s (SLCC) Emergency Medical Technician (EMT) ... Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support their first ...
(Date:12/6/2019)... , ... December 06, 2019 , ... TIME For ... 2019, spotlighting a mix of educational, innovative, and fun destinations that are tailored to ... of the 50 coolest places. , To assemble the list, TIME for Kids gathered ...
Breaking Medicine News(10 mins):